Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 00847G804 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
Invus Global Management, LLC
13G
|
10.0% |
7/17/2026
Event 7/13/2026
|
||
| Invus Public Equities, L.P. | 8.8% | |||
| Invus Public Equities Advisors, LLC | 8.8% | |||
| Invus Global Management, LLC | 8.8% | |||
| Siren, L.L.C. | 8.8% | |||
| Avicenna Life Sci Master Fund LP | 1.3% | |||
| Avicenna Life Sci Master GP LLC | 1.3% | |||
| Ulys, L.L.C. | 1.3% | |||
| Raymond Debbane | 10.0% | |||
|
RA Capital Management, L.P.
13G
|
9.9% |
7/20/2026
Event 7/13/2026
|
||
| RA Capital Management, L.P. | 9.9% | |||
| Peter Kolchinsky | 9.9% | |||
| Rajeev Shah | 9.9% | |||
| RA Capital Healthcare Fund, L.P. | 9.9% | |||
| BlackRock, Inc. 13G | 6.0% |
7/27/2026
Event 6/30/2026
|
||
|
Zynext Ventures USA LLC
13D
|
5.9% |
1/23/2026
Event 1/15/2026
|
||
| Zynext Ventures USA LLC | 5.9% | |||
| Zynext Ventures Pte Ltd | 5.9% | |||
| Zydus Lifesciences Ltd | 5.9% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (1) | ||||
| Vanguard Group Inc 13G/A | 0% |
3/26/2026
Event 3/13/2026
|
||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 4 | 23.7 k | $235 k |
| 2026 Q2 | 108 | 14.2 M | $43.6 M |
| 2026 Q1 | 91 | 9.21 M | $30.8 M |
| 2025 Q4 | 102 | 10.1 M | $31.8 M |
| 2025 Q3 | 95 | 8.82 M | $34.0 M |
| 2025 Q2 | 102 | 8.95 M | $40.9 M |
| 2025 Q1 | 95 | 8.86 M | $13.3 M |
| 2024 Q4 | 92 | 8.44 M | $23.1 M |
| 2024 Q3 | 105 | 8.35 M | $45.8 M |
| 2024 Q2 | 96 | 9.29 M | $156 M |
| 2024 Q1 | 10 | 1.01 M | $653 k |